It’s only fair to share… Pimavanserin MF C25H34FN3O2 MW 427.555 Pimavanserin, ACP 103, ACP-103; BVF-048 N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide, 706779-91-1 (Pimavanserin ) 706782-28-7 (Pimavanserin Tartrate) for treatment of psychotic symptoms in patients with Parkinson’s disease WATCH OUT AS THIS POST IS UPDATED……….. Trade Name：Nuplazid® MOA：5-HT2A inverse agonist Indication：Hallucinations and delusions associated with Parkinson’s disease psychosis Company：Acadia (Originator) APPROVED US FDA 2016-04-29, ACADIA PHARMS INC, (NDA) …
Category «Uncategorized»
Ranolazine, 雷诺嗪
It’s only fair to share… Ranolazine 雷诺嗪 MF C24H33N3O4 MW 427.536 Approvals FDA 2006, EMA 2008 for chronic angina Sponsor/Developer: Gilead Mechanism of action: Late sodium current inhibitor Indication (Phase): Type 2 diabetes (Phase III) A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone (currently recruiting participants …
Imidafenacin, イミダフェナシン
It’s only fair to share… Imidafenacin イミダフェナシン Cas 170105-16-5 C20H21N3O, 319.408 APPROVED JAPAN 2015-07-29 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide 4-(2-methylimidazol-1-yl)-2,2-di(phenyl)butyramide D06273 KRP-197 KRP-197;ONO-8025 ONO-8025 UNII:XJR8Y07LJO Company：Kyorin (Originator), Ono (Originator) 4-(2-methyl-1-imidazolyl)- 2,2-diphenylbutyramide as a colorless needle: mp 189.0±190.0 C (from ethyl acetate:ethanol); High MS (EI+) m/z calcd for C20H21N3O 319.1685, found 319.1671; 1 H NMR (400 MHz, CDCl3) d 2.23 (3H, s), …
(3S)-3-[(2-amino-5-methoxypyrimidin-4-yl)amino]heptan-1-ol for the treatment of viral infections
It’s only fair to share… (3S)-3-[(2-amino-5-methoxypyrimidin-4-yl)amino]heptan-1-ol cas 1402802-45-2 JNJ ? WO 2012136834, WO 2014053595 for the treatment of viral infections Molecular Formula: C12H22N4O2 Molecular Weight: 254.32868 g/mol Inventors Gowan David Mc, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach, Applicant Janssen R&D Ireland (3S)-3-[(2-amino-5-methoxypyrimidin-4-yl)amino]heptan-1-ol Mark Hicken, …
ORM 10921
It’s only fair to share… ORM 10921 UNII-D26C95A960; D26C95A960; ORM-12741; ORM12741; ORM 12741; ORM-10921; (1S,12bS)-1-(Methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-1H-[1]benzofuro[2,3-a]quinolizine (1S,12bS)-1-(methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine 285.38, C18 H23 N O2 2H-Benzofuro[2,3-a]quinolizine, 1,3,4,6,7,12b-hexahydro-1-(methoxymethyl)-1-methyl-, (1S,12bS)- cas 610782-82-6 Belle David Din, Reija Jokela, Arto Tolvanen,Antti Haapalinna, Arto Karjalainen, Jukka Sallinen, Jari Ratilainen Applicant Orion Corporation David Din Belle Senior research scientist at Orion Corporation https://fi.linkedin.com/in/david-din-belle-a2594115 Jari Ratilainen https://fi.linkedin.com/in/jari-ratilainen-6a566218 Reija …
IPI-549
It’s only fair to share… IPI-549 CAS 1693758-51-8 MF : C30H24N8O2 Molecular Weight: 528.576 (S)-2-amino-N-(1-(8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Company Infinity Pharmaceuticals Inc. Description Small molecule inhibitor of phosphoinositide 3-kinase (PI3K) gamma Molecular Target Phosphoinositide 3-kinase (PI3K) gamma Mechanism of Action Phosphoinositide 3-kinase (PI3K) gamma inhibitor Therapeutic Modality Small molecule Latest Stage of Development Phase I Standard Indication Solid …
Ibipinabant Revisited
It’s only fair to share… Ibipinabant cas 464213-10-3; UNII-O5CSC6WH1T; BMS-646256; SLV-319; Molecular Formula: C23H20Cl2N4O2S Molecular Weight: 487.4015 g/mol (4S)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N’-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-N’-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N-methyl-4-phenyl-, (4S)- (4S)-3-(4-Chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N’-methyl-4-phenyl-1H-pyrazole-1-carboximidamide 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N‘-methyl-4-phenyl-, (4S)- (-)-(4S)-N-Methyl-N’-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine 4S)-(−)-3-(4-Chlorophenyl)-N-methyl-N‘-[(4-chlorophenyl)sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine It was originally developed by Solvay, which was acquired by Abbott in 2010. SLV 319, UNII:O5CSC6WH1T, (S)-SLV 319, BMS 646256, JD 5001 Originator Solvay Class Antipsychotics; Imides; Obesity therapies; Pyrazoles; Small molecules; Sulfonamides …
1, 2-Bis(4-(4-4-nitrophenyl)piperazin-1-yl)ethanone for androgen sensitive prostatic disorders
It’s only fair to share… 1, 2-Bis(4-(4-4-nitrophenyl)piperazin-1-yl)ethanone Molecular Formula: C22H26N6O5 Molecular Weight: 454.47904 g/mol CAS 330633-91-5 CDRI-? For treatment of androgen sensitive prostatic disorders 1, 2-Bis(4-(4-4-nitrophenyl)piperazin-1-yl)ethanone In the quest for novel scaffolds for the management of androgen sensitive prostatic disorders like prostate cancer and benign prostatic hyperplasia, a series of twenty-six aryl/heteroaryl piperazine derivatives have …
PF-04745637
It’s only fair to share… PF-04745637 cas 1917294-46-2 MW 509.00, MF C27 H32 Cl F3 N2 O2 Cyclopentanecarboxamide, 1-(4-chlorophenyl)-N-[2-[4-hydroxy-4-(trifluoromethyl)-1-piperidinyl]-3-phenylpropyl]- rac-1-(4-Chlorophenyl)-N-f2-r4-hvdroxy-4-(trifluoromethyl)piperidin-1-vn-3-phenylpropyDcyclopentanecarboxamide PRODUCT PATENT WO-2016067143-A1 Applicants: PFIZER INC. [US/US]; 235 East 42nd Street New York, New York 10017 (US) Inventors: SWAIN, Nigel Alan; (GB). PRYDE, David Cameron; (GB). RAWSON, David James; (GB). RYCKMANS, Thomas; (GB). SKERRATT, Sarah Elizabeth; (GB). …
ALMOREXANT REVISITED
It’s only fair to share… Almorexant; ACT-078573; (R)-2-((S)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide; Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011.[1] Development …